Method of inhibiting constitutively active phosphorylated FLT3 kinase
AssigneeArog Pharmaceuticals, Inc.
InventorVinay K. Jain
Life of this patent
Estimating the term…
Abstract
The present invention includes a method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or FLT3 tyrosine kinase expression in a subject with a proliferative disease by administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I: or pharmaceutically acceptable salt thereof.
Claims37
A method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or expression in a subject with a hematologic malignant neoplastic disorder which comprises administering to the subject having or suspected to have the hematologic malignant neoplastic disorder, a therapeutically or prophylactically effective amount of the compound of Formula 1:
- or a pharmaceutically acceptable salt or solvate thereof.
A method for treating a subject with a hematologic malignant neoplastic disorder comprising:
- administering to the subject in need of such treatment a therapeutically effective amount of Crenolanib or a pharmaceutically acceptable salt thereof, wherein the hematologic malignant neoplastic disorder is characterized by deregulated FLT3 receptor tyrosine kinase activity, the hematologic malignant neoplastic disorder is selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, Hodgkin's disease, myeloma, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), acute undifferentiated leukemia (AUL), anaplastic large-cell lymphoma (ALCL), prolymphocytic leukemia (PML), juvenile myelomonocytic leukemia (JMML), adult T-cell ALL, AML with trilineage myelodysplasia (AMLITMDS), mixed lineage leukemia (MLL), myeloproliferative disorders (MPD), or multiple myeloma (MM).
A method of specifically inhibiting an abnormal receptor tyrosine kinase comprising:
- obtaining a subject sample and determining which receptor tyrosine kinases are deregulated;
- identifying that the subject has a deregulated FLT3 receptor tyrosine kinase;
- and
- administering to a mammal having or suspected of having a hematologic malignant neoplastic disorder in need of such treatment a therapeutically effective amount of Crenolanib or a pharmaceutically acceptable salt thereof, wherein the abnormal receptor tyrosine kinase is a FLT3 receptor tyrosine kinase.
Dependencies are inferred from the claim text.